Compare IHRT & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHRT | SPRY |
|---|---|---|
| Founded | 1974 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 589.5M | 634.5M |
| IPO Year | 2019 | 2020 |
| Metric | IHRT | SPRY |
|---|---|---|
| Price | $2.81 | $5.62 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.25 | ★ $40.00 |
| AVG Volume (30 Days) | 585.6K | ★ 1.5M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.19 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,864,991,000.00 | $84,278,000.00 |
| Revenue This Year | $9.96 | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.27 | N/A |
| 52 Week Low | $2.05 | $4.91 |
| 52 Week High | $6.56 | $13.15 |
| Indicator | IHRT | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 43.72 |
| Support Level | $2.56 | $5.04 |
| Resistance Level | $3.39 | $6.58 |
| Average True Range (ATR) | 0.15 | 0.37 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 49.53 | 35.14 |
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.